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Population-Based Assessment of Non-Melanoma
Cancer Risk in Relatives of Cutaneous Melanoma
Probands
April A. Larson1,3, Sancy A. Leachman1,3, Mark J. Eliason3 and Lisa A. Cannon-Albright2
Using the unique Utah Population Database, which links Utah genealogical data with Utah cancer data, we
examined risks for other cancers among relatives of 4,079 melanoma cases. Age- and sex-specific rates for 35
different cancer sites were calculated, and used to estimate relative risks among relatives. In addition to the
well-recognized risk for melanoma among first-degree relatives, we found significantly increased risks for
prostate, breast, and colon cancers, non-Hodgkin’s lymphoma, and multiple myeloma, ranging from 32 to 72%
increased risk. Among second-degree relatives, in addition to increased risk for melanoma, we identified
significantly increased risks for prostate cancer and multiple myeloma (27 and 53% increase, respectively).
Among first-degree relatives of melanoma cases diagnosed before the age of 40 years, we found significantly
elevated risks for cutaneous melanoma (380% increase) and prostate cancer (83% increase). Significantly
increased risks for prostate cancer and multiple myeloma in both first- and second-degree relatives of
melanoma cases are suggestive of heritable cancer syndromes. The increased risks for five additional cancer
types in first-degree relatives of melanoma cases suggest that individuals with a family history of melanoma
should strictly adhere to recommended screenings for all cancers.
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INTRODUCTION
Cutaneous melanoma is the most lethal skin cancer in the
world, with a propensity toward metastasis, and is the fifth
and sixth most common cancer in men and women,
respectively, in the United States (Jemal et al., 2005).
Melanoma results from the accumulation of acquired or
inherited genetic mutations. Genetic studies of melanoma-
prone pedigrees led to the identification of melanoma
predisposition genes, including CDKN2A (MIM 600160)
(Cannon-Albright et al., 1992; Hussussian et al., 1994; Kamb
et al., 1994; Nobori et al., 1994), CDK4 (MIM 123829) (Zuo
et al., 1996; Soufir et al., 1998; Hayward, 2003), and p14/
ARF (MIM 600160) (Randerson-Moor et al., 2001; Rizos
et al., 2001; Hewitt et al., 2002). A member of a melanoma-
prone family, with or without an identifiable mutation, has a
35–70 times greater risk for melanoma than the general
population (Goldstein and Tucker, 2001). Families with a
mutation in a tumor suppressor or oncogene may also be at
increased risk for other cancers. Germline mutations in
CDKN2A predispose to both melanoma and pancreatic cancer
(Vasen et al., 2000; Parker et al., 2003; Goldstein, 2004).
In addition to genes, family members share environmental
and heritable traits, such as sun exposure, skin and hair color,
and density of nevi (Goldstein, 2004). It is not surprising that
first-degree relatives of any melanoma patient have a 2- to
3-fold increased risk for developing melanoma (Ford et al.,
1995; Cho et al., 2005). Relatives of melanoma patients,
whether or not they are part of a melanoma-prone family,
may also be at increased risk for developing non-melanoma
cancers. Little data have been published regarding the risk of
non-melanoma cancers in relatives of melanoma probands.
Better understanding of the risks for other cancers associated
with melanoma could generate additional hypotheses regard-
ing cancer predisposition, and provide more accurate risk
assessments for clinicians to share with patients and family
members. Identification of cancers associated with melano-
ma may aid in the discovery of the predisposition genes
responsible, and allows clinical care tailored to an indivi-
dual’s family cancer history. Here, we describe the risks of
cancer of all sites in relatives of melanoma patients, estimated
in Utah.
RESULTS
In the Utah Population Database (UPDB), 4,079 individuals
were diagnosed with cutaneous melanoma between 1966
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and 2002, and also have at least four generations of
genealogy data. Table 1 shows relative risk (RR) estimates
for those cancers for which RRs were at least nominally
significantly elevated (Po0.05) among the 30,504 first-
degree relatives of the cutaneous melanoma cases. The RR
for melanoma among the first-degree relatives is 3.14 (95%
confidence interval (CI): 2.77, 3.55). For five cancer sites
other than melanoma, significantly elevated RRs in first-
degree relatives were observed, even after correction for
multiple testing. These cancers include prostate, breast, and
colon carcinomas, non-Hodgkin’s lymphoma, and multiple
myeloma. A significantly decreased risk was not observed for
any cancer site.
Table 2 shows RR estimates for those cancers for which
RRs were at least nominally significantly elevated (Po0.05)
among the 84,153 second-degree relatives of the cases. The
RR for melanoma among second-degree relatives of melano-
ma cases in the UDPB is significantly increased; RR¼1.64
(95% CI: 1.44, 1.86). After correction for multiple testing,
both prostate cancer and multiple myeloma were also
Table 1. Elevated risks for other cancers (Po0.05, uncorrected) in the 30,504 first-degree relatives of the 4,079
melanoma cases in UPDB, ranked by significance
Cancer type Observed Expected P-value RR 95% CI
Cutaneous melanoma 258 82.0 o0.00001 3.14 2.77, 3.55
Prostate 536 402.8 o0.00001 1.33 1.22, 1.45
Breast 427 324.3 o0.00001 1.32 1.20, 1.45
Colon 219 160.4 o0.00001 1.37 1.19, 1.56
Non-Hodgkin’s lymphoma 119 84.0 0.0002 1.42 1.17, 1.69
Multiple myeloma 52 30.3 0.0002 1.72 1.28, 2.25
Urinary/bladder 118 87.9 0.0013 1.34 1.11, 1.61
Brain 50 31.8 0.0017 1.57 1.17, 2.07
Stomach 59 39.6 0.0023 1.49 1.14, 1.92
Eye 16 7.1 0.0028 2.25 1.29, 3.66
Male genital 8 2.4 0.0035 3.31 1.43, 6.51
Pancreas 64 44.8 0.0041 1.43 1.10, 1.82
Leukemia 92 70.2 0.0072 1.31 1.06, 1.61
Rectum 85 66.1 0.014 1.29 1.03, 1.59
Lip 45 32.0 0.018 1.40 1.02, 1.88
Anus 16 10.0 0.047 1.37 1.32, 1.42
CI, confidence interval; RR, relative risk; UPDB, Utah Population Database.
Table 2. Elevated RRs for other cancers (Po0.05, before correction) in the 84,153 second-degree relatives of the
4,079 melanoma cases, ranked by significance
Cancer type Observed Expected P-value RR 95% CI
Prostate 1,013 800.0 o0.00001 1.27 1.19, 1.35
Cutaneous melanoma 241 147.1 o0.00001 1.64 1.44, 1.86
Multiple myeloma 91 59.4 0.00008 1.53 1.23, 1.88
Leukemia 188 149.9 0.0015 1.25 1.08, 1.45
Pancreas 124 93.8 0.0016 1.32 1.10, 1.45
Breast 672 599.7 0.0023 1.12 1.04, 1.21
Eye 26 14.6 0.0046 1.78 1.16, 2.60
Rectum 158 127.9 0.0046 1.24 1.05, 1.44
Non-cutaneous melanoma 22 12.7 0.011 1.73 1.09, 2.62
Colon 374 333.3 0.015 1.12 1.01, 1.24
CI, confidence interval; RR, relative risk.
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observed in significant excess among second-degree rela-
tives.
Because individuals with more than one primary cuta-
neous melanoma are considered more likely to have disease
of a genetic origin (Bale et al., 2002), we estimated RR for
other cancers among the 730 first-degree relatives of 95
individuals who had more than one primary melanoma
(Table 3). The RR for melanoma among the first-degree
relatives (RR¼8.53) was the only significantly increased risk
observed for any cancer site after correction, although
nominally significantly elevated risk was noted for urinary/
bladder cancers (RR¼ 3.99).
Similarly, because early-onset cancers are thought more
likely to be genetic in origin (Bale et al., 2002), we estimated
RR for other cancers among the 7,662 first-degree relatives of
the 1,218 melanoma cases who were diagnosed before the
age of 40 years (Table 4). The RR for melanoma among the
first-degree relatives of the early-onset cases was significantly
elevated, as was the risk for prostate cancer.
We also estimated RR for other cancers in the first-degree
relatives of individuals whom we defined as familial
melanoma cases. We identified 131 independent melanoma
cases that had at least one first-degree relative with
melanoma. Table 5 shows the RR estimates for other cancers
observed in excess among the 1,238 first-degree relatives
(without duplication) of these ‘‘familial’’ melanoma cases.
The majority of the clusters identified included just two cases,
but we identified four pedigrees with 42 affected first-degree
relatives: one case with two affected siblings and three
affected offspring; one case with an affected parent and two
affected offspring; and two cases with two affected siblings
each. Only prostate cancer was observed in excess among
the first-degree relatives of the familial melanoma cases.
We additionally evaluated the risk of cancer of other sites
in the 4,079 melanoma cases themselves. Six hundred and
fourteen melanoma cases had at least one additional cancer
diagnosis that was not a cutaneous melanoma. Two hundred
and sixty-seven of the cases were diagnosed with the
cutaneous melanoma first, and 347 had the melanoma
diagnosis following diagnosis for another cancer. Signifi-
cantly increased risks (Po0.00025 after correction) were
identified for several cancers, including breast cancer
(n¼90), lip cancer (n¼21), non-skin melanoma (n¼ 7),
prostate cancer (n¼ 175), and testicular cancer (n¼ 12).
We have summarized all the risks represented in Tables
1–5 for different relationships of different subsets of melano-
ma cases in Table 6, by cancer site. Risks for melanoma were
significantly elevated (Po0.0001) among all relatives con-
sidered, and for all the subsets of melanoma cases
considered. Prostate cancer and breast cancer risks were
elevated in relatives of multiple subsets of melanoma cases.
Other cancer sites observed in excess in relatives of more
Table 3. Elevated RRs for other cancers (Po0.05, before correction) in the 730 first-degree relatives of the
95 melanoma cases with two or more primary melanomas
Cancer type Observed Expected P-value RR 95% CI
Cutaneous melanoma 18 2.1 o0.00001 8.53 5.06, 13.45
Urinary/bladder 9 2.3 0.00056 3.99 1.82, 7.57
CI, confidence interval; RR, relative risk.
Table 4. Elevated RRs for other cancer sites (Po0.05, before correction) in the 7,662 first-degree relatives of 1,218
early diagnosed melanoma cases (onset o age 40 years), ranked by significance
Cancer type Observed Expected P-value RR 95% CI
Cutaneous melanoma 76 15.8 o0.00001 4.80 3.78, 6.01
Prostate 91 49.8 o0.00001 1.83 1.47, 2.24
Breast 66 47.1 0.0053 1.40 1.08, 1.78
CI, confidence interval; RR, relative risk.
Table 5. Elevated RRs for other cancer sites (Po0.05, before correction) in the 1,238 first-degree relatives of the
131 familial melanoma cases (cases with at least one first-degree relative affected), ranked by significance
Cancer type Observed Expected P-value RR 95% CI
Prostate 38 19.3 0.00011 1.97 1.39, 2.70
CI, confidence interval; RR, relative risk.
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than one subset of melanoma cases included colon, multiple
myeloma, urinary/bladder, eye, pancreas, leukemia, and
rectum.
DISCUSSION
The risk of melanoma in first-degree relatives of melanoma
cases, as estimated from the UPDB, agrees with previously
published risk estimates for melanoma that range from two to
three times the population risk (Ford et al., 1995; Cho et al.,
2005). The increased risks observed for other malignancies in
Utah confirm previously published population-based studies,
and introduce new, unreported associations.
We previously reported risks of other cancers in the
relatives of melanoma cases, using a much earlier and
smaller version of the UPDB (Goldgar et al., 1994). In that
study, we estimated risks of other cancers in the first-degree
relatives of 1,505 melanoma cases. The previous analysis had
a significantly smaller sample size, and did not distinguish
cutaneous melanomas, as we have here. In our previous
study, significantly increased risks were observed for mela-
noma (RR¼2.10; 95% CI: 1.41, 2.94), and for brain/central
nervous system cancers (RR¼1.68; 95% CI: 1.2, 2.3) in first-
degree relatives of all melanoma cases. A significantly
increased RR for melanoma among the first-degree relatives
of melanoma cases diagnosed before the age of 50 years was
also reported.
There have been few other studies reporting the risk of
non-melanoma malignancies in relatives of melanoma cases.
Hemminki et al. (2001, 2003) examined familial risks for
melanoma cases in the Swedish Family Cancer Database.
Associations were found with pancreatic, breast, testicular,
nervous system cancers, and non-Hodgkin’s lymphomas.
Borg et al. (2000) reported that families with 113insArg
mutations in CDKN2A had a high frequency of breast cancer
(P¼0.0014) and pancreatic cancer (Po0.0001). Debniak
et al. (2003) evaluated the risk of malignancies of different
sites in melanoma patients and their first-degree relatives in
families with cancer aggregations. They observed increased
risk of breast cancer and liver cancer. Chatterjee et al. (2004)
reported an increased risk of melanoma of the skin (hazard
ratio, 2.9; 95% CI: 1.08, 7.75) in first-degree relatives of non-
Hodgkin’s lymphoma cases. Hill et al. (2004) reported an
increased risk of meningioma among persons reporting a
family history of melanoma (odds ratio, 4.2; 95% CI: 1.2,
15.0). These studies typically use very different data sources
and study designs than our UPDB analysis, and there is only
some overlap of findings. Analysis of the population-based
UPDB allows us to avoid the ascertainment and recall bias
typically encountered in these studies.
The clustering of cancers of different sites within families
may be explained by coincidence, shared environmental
exposures, heritability, commonality of genetic mutations, or
some combination of these. CDKN2A is the most common
known melanoma predisposition gene. It has been associated
with both melanoma and pancreatic cancer (Vasen et al.,
2000; Parker et al., 2003; Goldstein, 2004). In our analysis,
pancreatic cancer was not significantly increased among
relatives of melanoma cases. This is not surprising, as non-
CDKN2A melanoma-prone families do not have a reported
increased risk of pancreatic cancer (Rieder and Bartsch,
2004). A recent survey of familial melanoma clusters in Utah
estimated that only 8–10% are due to segregating CDKN2A
mutations (Eliason et al., 2006); it is becoming clear that not
all p16 mutation-carrying pedigrees are predisposed to
pancreatic cancer (Goldstein, 2004). The combination of
the low number of p16 pedigrees in Utah and the lack of
pancreatic cancer involvement in most of the studied p16
pedigrees may explain the lack of increased risk for
pancreatic cancer in the Utah melanoma population.
The most consistent observations of co-aggregation of
cancers with melanoma in our study were prostate cancer
and breast cancer, which we observed in significant excess in
Table 6. Summary of elevated risks in relatives of melanoma cases (Po0.05, uncorrected)
Probands:
All melanoma
cases
All melanoma
cases
Melanoma cases
with other cancer
Melanoma cases
dx oage 40 years
Familial melanoma
cases
Relatives: First Second First First First
Cancer type
Cutaneous melanoma + + + + +
Prostate + + + +
Breast + + +
Colon + +
Multiple myeloma + +
Urinary/bladder + +
Eye + +
Pancreas + +
Leukemia + +
Rectum + +
dx, diagnosed.
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both first- and second-degree relatives of melanoma cases,
and in relatives of early-onset melanoma cases. In addition,
prostate cancer was observed in excess among the relatives of
familial melanoma cases. These results are consistent with
our previous report of the elevation of melanoma risk among
relatives of prostate cancer cases (Cannon-Albright et al.,
2005), and suggest a heritable syndrome involving predis-
position for both melanoma and prostate cancer. Although
the association between melanoma and prostate cancer is
unclear, one commonality between these tumor types is the
expression of testosterone receptors and potential sex
hormone sensitivity (Morvillo et al., 2002). Melanoma occurs
more frequently in men than women. Further, it has been
suggested that changes in nevi during pregnancy may be due
to activation of the testosterone receptors by high levels of
estrogen. Additional investigation is needed to establish the
molecular relationship between melanoma and prostate
cancer.
A better understanding of associations with melanoma and
other cancer sites may allow development of tailored
screening recommendations for relatives of melanoma cases,
and may provide important clues into molecular pathways of
melanoma genesis. The elucidation of these pathways will
generate new, better treatments for melanoma and associated
cancers. Further analyses of Utah high-risk pedigrees with
excesses of melanoma and other cancers will lead to
identification of the genes responsible.
MATERIALS AND METHODS
Utah population database
The UPDB contains multiple computerized data sources for Utah,
including a genealogy of Utah founders and their descendants,
linked to the Utah Cancer Registry (Skolnick, 1980). Approximately
2.5 million individuals in the genealogy have at least four
generations of data. The Utah population has normal levels of
inbreeding, and is genetically a representative of Northern Europe
(McLellan et al., 1984; Jorde, 1989).
The Utah Cancer Registry was established in 1966 and became a
National Cancer Institute’s Surveillance, Epidemiology, and End
Results Registry in 1973. All cancers in the state are reportable by
law. The records in the Utah Cancer Registry are linked to the UPDB
genealogy on an annual basis. In the case of multiple cancers in an
individual, only independent primaries are reported. Surveillance,
Epidemiology, and End Results registries follow much more stringent
guidelines when coding multiple primary melanomas of the skin
than other primaries. In order for a melanoma case to be considered
a multiple primary, at least one of the following criteria must be met:
the first three digits of the International Classification of Diseases and
Injuries code are different, or there has been a lapse of more than
2 months between the diagnoses — with no evidence of metastasis
or recurrence, or the tumor has a different histology at the third digit,
or the tumors have different laterality.
In the set of 2.5 million individuals with at least four generations
of genealogy, there are over 94,000 linked cancers. Standardized
incidence ratios for cancers of most sites are lower in Utah than in
the United States, probably due to lower rates of smoking in the Utah
population (1988); however, the standardized incidence ratios for
melanoma are significantly higher.
RR in relatives
We estimate the RR of cancer among relatives using rates of cancer
estimated internally within the UPDB (Cannon-Albright et al., 2005).
All 2.5 million individuals in the UPDB with at least four generations
of genealogy data are assigned membership in different birth year-,
sex-, and birthplace-specific (Utah or not Utah) cohorts. Cohort-
specific rates for a cancer are estimated by summing the total cohort-
specific number of individuals with the cancer, divided by the total
number of individuals in the cohort within UPDB. Expected numbers
of cancer cases among relatives are estimated by multiplying the
number of relatives in each cohort by the cohort-specific rate for the
cancer of interest, then summing over all cohorts.
For a specific cancer, observed and expected numbers of cases
among the relatives of cases are summed over all cohorts. The RR is
the ratio of observed to expected cancers among all relatives. This
ratio is an unbiased estimate of RR of cancer for relatives. Exact one-
sided Poisson probabilities are calculated under the null hypothesis
RR¼ 1.0, assuming that the number of observed cases follows a
Poisson distribution with mean equal to the expected number of
cancers.
Because we have examined RRs for 34 different cancer sites in
multiple groups (first- and second-degree relatives of melanoma
cases, early-onset melanoma cases, cases with multiple primary
melanomas, and familial melanomas), a correction for multiple
testing is required. We apply a conservative Bonferroni correction
(conservative because the hypothesis tests are not all independent) to
adjust for the 34 5 tests performed. For a significant result, we
consider a threshold of 0.05/200, or P-value o0.00025.
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